We’re back from the World Orphan Drug Congress USA and excited to share our presentation with you!
Aparito CEO Dr Elin Haf Davies presented a session titled Co-creation with Patients: How to develop meaningful Clinical Outcome Assessments (COAs), a topic that delves into the impact of patient-driven COAs on trial outcomes.
Digital endpoints driven by patient needs
A well-planned COA strategy in rare disease and pediatric trials is critical to support the selection and interpretation of COA endpoints.
Aparito can provide early-stage support with input from Patient Group Accelerator Programme to guide Clinical Development.
Adaptive study designs have support from regulators
Comprehensive knowledge of a disease (especially rare disease) can help design and conduct adequate and well-controlled clinical trials of adequate duration with clinically meaningful endpoints.
Clinically meaningful and relevant endpoints require informative natural history studies and patient input.
Registry studies gather valuable data from those living with rare diseases
Enabling patients to enroll in a registry wherever they live in the world allows patients and caregivers to add their own data to the nGD-specific patient-reported outcome (PRO) and caregiver-reported outcome (ObsRO) as per the IGAs’ GARDIAN Registry.
Download the slides here!
Aparito and the Atom5™ clinical trial platform
Patients living with life-limiting diseases need access to clinical trials and innovative treatments.
Aparito provides that access, wherever patients are.
We provide a patient-centric clinical trial platform that integrates clinical & regulatory expertise to capture patient data and develop digital endpoints for hybrid and decentralized clinical trials to streamline the drug development process with unique video capture & analysis capabilities.